Skip to content
DraconiticResearch
Search Sources API
181,713 studies31 sourcesUpdated 19 min ago
Peer-reviewedCC BY 4.0Cancers

Impact of Remote Symptom Monitoring on Acute Care Utilization in Patients with Advanced Cancer Undergoing Phase I Therapies: Secondary Analysis of a Randomized Clinical Trial

  • Jack Stover1
  • Matthew Meranda1
  • Ishwaria M. Subbiah2
  • Minxing Chen3
  • Sanjay Shete3
  • David Hong4
  • Eduardo Bruera1
  • David Hui1,5,6
6 affiliations
  1. 1Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
  2. 2Sarah Cannon Research Institute, Nashville, TN 37203, USA
  3. 3Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
  4. 4Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
  5. 5Center for Goal Concordant Care Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
  6. 6Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Open at sourceDOICite

Abstract

Purpose: Patients undergoing phase I cancer therapies experience high symptom burden and complications that may lead to emergency department (ED) visits and hospitalizations. It is unclear whether remote symptom monitoring (RSM) reduces acute care utilization. We conducted a secondary analysis of a randomized clinical trial to determine if incorporating RSM into specialist palliative care (SPC) would reduce ED visits/hospitalizations. Methods: Patients with advanced cancer undergoing phase I therapies were randomized to SPC alone or SPC+RSM. Primary outcomes were ED visit and hospitalization frequencies over 6 months. We also assessed presenting concern, presentation etiology, and potential avoidability with two independent reviewers. Results: Among 100 patients (mean age 56, 63% female, median survival 221 [95% CI 171, 271] days), 43 were in the SPC group and 57 were in the SPC+RSM group. A total of 22/43 (51%) SPC patients and 30/57 (53%) SPC+RSM patients had at least one ED visit over 6 months (p = 0.58), while 18/43 (42%) SPC patients and 21/57 (37%) had at least one hospitalization over 6 months (p = 0.56). The most common presenting symptoms were pain (ED 27%, hospitalizations 29%) and respiratory symptoms (ED 22%, hospitalization 22%). The main reasons for acute care encounters were disease progression (ED 49%, hospitalizations 58%) and acute complications (ED 26%, hospitalizations 28%). Only 4/84 (5%) ED visits and 0/57 (0%) of the hospitalizations were deemed avoidable. Conclusions: Acute care utilization was high in phase I patients. RSM did not reduce ED visits/hospitalizations, which were mostly unavoidable. Our findings highlight the need for novel strategies to support this population.

Related

  1. Utilization and outcomes of nutrient-stimulated hormone therapies in patients undergoing bariatric surgery
    Claudia R. Villatoro Santos, Hector D. Estrada Tock, Haoran Tang +4
    International Journal of Obesity (2005)Peer-reviewedCC BY 4.0Full textSurgery & anaesthesiaPMC
  2. Factors Associated with Patient Interest in a Digital Exercise and Mind–Body Program for Patients Undergoing Active Cancer Treatment: A Secondary Analysis of a Randomized Clinical Trial
    Karolina Bryl, Esin Namoglu, Susan Chimonas +4
    CancersPeer-reviewedCC BYFull textOncologyEurope PMC
  3. Cost-effectiveness of adding enzalutamide vs standard non-steroidal antiandrogen drugs for patients with metastatic hormone-sensitive prostate cancer undergoing standard first-line therapy: a within-trial, secondary end-point analysis of the ENZAMET phase 3, international randomized trial (ANZUP 1304)
    Chi Kin Law, Martin R. Stockler, Andrew J. Martin +3
    EClinicalMedicinePeer-reviewedCC BYFull textGeneral medicineEurope PMCCrossref
  4. Continuous intra-arterial versus noninvasive blood pressure monitoring for preventing hypotension during anesthesia induction in patients aged ≥ 75 years undergoing noncardiac surgery: a randomized controlled trial.
    Yihang Li, Shuang Liang, Yuqi Zhang +3
    BMC anesthesiologyPeer-reviewedCC BY-NC-NDFull textSurgery & anaesthesiaEurope PMCDOAJ
  5. Post–Acute Care Facility Utilization and Outcomes Among Medicare Beneficiaries Undergoing Inpatient Cancer Surgery
    Daniel E. Lage, Mary Beth Landrum, Alex Melamed +3
    JAMA Network OpenPeer-reviewedCC BY-NC-NDFull textOncologyCrossrefEurope PMCPMC

Cite

BibTeXRIS
BibTeX
@article{stover2026impact,
  title = {{Impact of Remote Symptom Monitoring on Acute Care Utilization in Patients with Advanced Cancer Undergoing Phase I Therapies: Secondary Analysis of a Randomized Clinical Trial}},
  author = {Jack Stover and Matthew Meranda and Ishwaria M. Subbiah and Minxing Chen and Sanjay Shete and David Hong and Eduardo Bruera and David Hui},
  journal = {Cancers},
  year = {2026},
  month = oct,
  doi = {10.3390/cancers18213499},
  url = {https://www.mdpi.com/2072-6694/18/21/3499},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Impact of Remote Symptom Monitoring on Acute Care Utilization in Patients with Advanced Cancer Undergoing Phase I Therapies: Secondary Analysis of a Randomized Clinical Trial
AU  - Jack Stover
AU  - Matthew Meranda
AU  - Ishwaria M. Subbiah
AU  - Minxing Chen
AU  - Sanjay Shete
AU  - David Hong
AU  - Eduardo Bruera
AU  - David Hui
PY  - 2026
DA  - 2026/10/30
JO  - Cancers
DO  - 10.3390/cancers18213499
UR  - https://www.mdpi.com/2072-6694/18/21/3499
AB  - Purpose: Patients undergoing phase I cancer therapies experience high symptom burden and complications that may lead to emergency department (ED) visits and hospitalizations. It is unclear whether remote symptom monitoring (RSM) reduces acute care utilization. We conducted a secondary analysis of a randomized clinical trial to determine if incorporating RSM into specialist palliative care (SPC) would reduce ED visits/hospitalizations. Methods: Patients with advanced cancer undergoing phase I therapies were randomized to SPC alone or SPC+RSM. Primary outcomes were ED visit and hospitalization frequencies over 6 months. We also assessed presenting concern, presentation etiology, and potential avoidability with two independent reviewers. Results: Among 100 patients (mean age 56, 63% female, median survival 221 [95% CI 171, 271] days), 43 were in the SPC group and 57 were in the SPC+RSM group. A total of 22/43 (51%) SPC patients and 30/57 (53%) SPC+RSM patients had at least one ED visit over 6 months (p = 0.58), while 18/43 (42%) SPC patients and 21/57 (37%) had at least one hospitalization over 6 months (p = 0.56). The most common presenting symptoms were pain (ED 27%, hospitalizations 29%) and respiratory symptoms (ED 22%, hospitalization 22%). The main reasons for acute care encounters were disease progression (ED 49%, hospitalizations 58%) and acute complications (ED 26%, hospitalizations 28%). Only 4/84 (5%) ED visits and 0/57 (0%) of the hospitalizations were deemed avoidable. Conclusions: Acute care utilization was high in phase I patients. RSM did not reduce ED visits/hospitalizations, which were mostly unavoidable. Our findings highlight the need for novel strategies to support this population.
SN  - 2072-6694
ER  -